News
Terapet's New Investment Round of CHF 2,3 M
Today, we are pleased to announce the new investment of CHF 2,3 million as the first closing of the Pre-Series A investment round. This funding supports the commercialization of Terapet’s first product, Qualγscan and the development of new nuclear imaging products. We would like to take this opportunity to thank…
Terapet SA and The Politecnico di Milano – Dipartimento di Elettronica, Informazione e Bioingegneria are pleased to announce that they have entered a Research and Development partnership for the coming three years
Geneva, June 1st, 2021 Terapet SA, a privately held Swiss MedTech company developing innovative solutions for a safer, more precise, and time-saving proton therapy for cancer treatment, announced today the start of a new Research and Development partnership with The Politecnico di Milano – Dipartimento di Elettronica, Informazione e Bioingegneria.…
Terapet highlighted by Venture Kick in Annual Report 2020
Read Venture Kick Annual Report: Annual Report 2020
Terapet SA is proud to announce: Terapet together with their world class R&D partners (CERN, Karolinska Institute and Skandion Clinic) are awarded a total of CHF 1'530'000 non-dilutive funds
Geneva, January 1 st , 2021 Terapet SA, a privately held Swiss MedTech company developing innovative solutions for a safer, more precise, and time-saving proton therapy for cancer treatment, announced today the combined successful awards of a total of about CHF 1’530’000 non-dilutive funds. The combined funding supports the development…
Christina, our CEO, invited to “Meeting Women Executives in Tech” event organized by Science2Market at Pulse Incubateur HES
Excited to celebrate and empower women in tech in Geneva. Join us for an exciting discussion on the road to innovation and entrepreneurship. https://www.science2market.ch/event-details/yes-you-can-meet-women-executives-in-tech Organized at Pulse Incubateur HES with the support of Innosuisse – Swiss Innovation Agency.
Find Terapet SA on Page 119 in Swiss Startup Guide edition 2020/2021, among the '12 companies on the way to success'
Find Terapet on Page 119, among the '12 companies on the way to success'.
Christina, our CEO, invited to "Moving out of Academia to MedTech" as one of the panelists at this CERN alumni event
After 12 years at CERN, Christina co-founded Terapet SA, a Geneva-based MedTech company in 2019. Meet our CEO Christina at "Moving out of academia to Medtech" and she will share her journey with you.
Terapet wins Venture Kick Stage III, total CHF 150'000
Terapet’s real-time tracking of proton therapy dosage-delivery for cancer patients wins CHF 150,000
Today, Terapet is proud to announce the successful closing of the seed investment round of CHF 1 Million.
Today, Terapet is proud to announce the successful closing of the oversubscribed seed investment round of CHF 1 Million. This funding supports the development of our first full-scale prototype to be installed for clinical validation. This round was contributed by our new investors: EFI (Efficient Frontier Investing), Nina Capital, FSI…
Terapet: one of 10 Venture Finalists within Health & Nutrition vertical of this year's venture competition
Out of 327 submissions, the experts of Venture.ch chose 10 most promising startups in each of the verticals. It is our pleasure to be one of the top 10 Health & Nutrition finalists of this year’s Venture competition.
Terapet: one of Venture Leaders Life Science 2020. Representing Switzerland in the world capital of life sciences.
10 outstanding startups have been selected for this year’s Venture Leaders Life Sciences program. The winners will be celebrated at the Swiss Biotech Day in September and then travel to Boston, United States, for a week-long roadshow with the Swiss National Startup Team in November. Learn more!
Terapet: selected by Bilan as Top 50 Swiss Startups in which to invest in 2020
Terapet: selected by Bilan as Top 50 Swiss Startups in which to invest in 2020.
Terapet SA accepted to the EIT Health Investor Network
We are happy to announce that Terapet SA has gone through the EIT selection process and we have met the requirements to enter the EIT Health Investor Network. EIT (European Institute of Innovation and Technology) is an EU body created by the European Union in 2008 to strengthen Europe’s ability…
Terapet SA: a member of Swiss MedTech
Today Terapet became a member in the Swiss MedTech community. Swiss Medtech was established on 12 June 2017 following the merger of two national medtech organizations, FASMED and Medical Cluster. The new association represents the interests of the Swiss medtech industry. The aim is to maintain international competitiveness, innovative…
Today Terapet SA is featured as one of the Top10 Swiss MedTech rising stars by Venturelab
10 Swiss Medtech Startups to Watch in 2020 Thanks to Venturelab to select Terapet SA as one of Top10 Swiss MedTech Startups to Watch in 2020. Read more: Venturelab link.
Terapet SA selected as one of the six high-tech startups in the Israel-Swiss Lean Launchpad program
Once again we thank Innosuisse – Agence suisse pour l’encouragement de l’innovation for their constant trust and support. Terapet is among the 6 high-tech startups which have been selected by Innosuisse for the Israel-Swiss Lean Launchpad program. This exchange program will give the companies the opportunity to attend workshops while…
TERAPET passed Venture Kick Stage 2 and won CHF 40’000
Today, TERAPET passed Venture Kick Stage 2 and won CHF 40'000.
TERAPET SA incorporated and we officially joined Fongit
Since 27.11.2019, Terapet SA was incorporated and officially joined Fongit, Geneva. Terapet SA successfully closed a pre-seed round and welcomed two new board of directors (Didier Cowling and Antonio Gambardella) to join our company.
TERAPET among Top10 at Swiss Innovation Challenge 2019
Terapet has successfully reached Top10 of this year's Swiss Innovation Challenge and was one of 29 finalists over 140 initial participants.
Terapet is featured on the front page of l'agefi today
Terapet is featured on the front page of l’agefi on Monday’s edition. Thank you so much to the great team!
CHF 100,000 to make proton therapy more effective
Terapet, a startup based near Nyon, has just been awarded a CHF 100,000 Tech Seed loan from Vaud’s Foundation for Technological Innovation (FIT). Read press release from Startupticker.ch.
TERAPET passed Venture Kick Stage 1 and won CHF 10'000
Yesterday, TERAPET passed Venture Kick Stage 1 and won CHF 10'000.
TERAPET attending ISOP2019 (International Symposium on Proton Therapy), Madrid
This year, ISOP3 was held in Madrid, co-organized by QuirónSalud and IBA. Our co-founder, Prof. Raymond Miralbell, Medical Director at the first center for proton therapy in Spain, that is expected to be operational by the end of this year, was one of the main organizers for this event and…
TERAPET wins Swiss BIC of CERN Technologies and receives a cash grant of CHF 50,000
TERAPET wins the 2019 Swiss BIC of CERN Technologies at PARK INNOVAARE next to PSI, Villigen in Switzerland and receives a cash grant of CHF 50,000.
Startupticker.ch: BIC of CERN selects Arc Power and Terapet as new incubatees
Swiss BIC of CERN Technologies offers a two-year entrepreneurship program to support high tech startups in implementing their ideas. During the incubation, participants benefit from a wide range of offers including access to accelerator technology expertise. Each of the companies receives a cash grant of 50’000CHF. Read the press release…
